CN102281877B - 苯达莫司汀的游离碱形式 - Google Patents

苯达莫司汀的游离碱形式 Download PDF

Info

Publication number
CN102281877B
CN102281877B CN201080004743.6A CN201080004743A CN102281877B CN 102281877 B CN102281877 B CN 102281877B CN 201080004743 A CN201080004743 A CN 201080004743A CN 102281877 B CN102281877 B CN 102281877B
Authority
CN
China
Prior art keywords
free base
bendamustine free
bendamustine
diffraction pattern
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080004743.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102281877A (zh
Inventor
劳伦特·D·库瓦西耶
马克·伊迪莱斯顿
柯蒂斯·R·哈尔蒂万格
罗伯特·E·麦凯恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102281877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN102281877A publication Critical patent/CN102281877A/zh
Application granted granted Critical
Publication of CN102281877B publication Critical patent/CN102281877B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201080004743.6A 2009-01-15 2010-01-14 苯达莫司汀的游离碱形式 Expired - Fee Related CN102281877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
US61/144,843 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310425128.8A Division CN103554030A (zh) 2009-01-15 2010-01-14 苯达莫司汀游离碱的新颖形式

Publications (2)

Publication Number Publication Date
CN102281877A CN102281877A (zh) 2011-12-14
CN102281877B true CN102281877B (zh) 2014-07-23

Family

ID=42008533

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080004743.6A Expired - Fee Related CN102281877B (zh) 2009-01-15 2010-01-14 苯达莫司汀的游离碱形式
CN201310425128.8A Pending CN103554030A (zh) 2009-01-15 2010-01-14 苯达莫司汀游离碱的新颖形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310425128.8A Pending CN103554030A (zh) 2009-01-15 2010-01-14 苯达莫司汀游离碱的新颖形式

Country Status (16)

Country Link
US (1) US8076366B2 (enExample)
EP (1) EP2387400A1 (enExample)
JP (1) JP2012515210A (enExample)
KR (1) KR20110110293A (enExample)
CN (2) CN102281877B (enExample)
AU (2) AU2010204765A1 (enExample)
BR (1) BRPI1004922A2 (enExample)
CA (1) CA2749101A1 (enExample)
EA (1) EA020767B1 (enExample)
IL (1) IL213725A0 (enExample)
MX (1) MX2011007557A (enExample)
NZ (1) NZ594010A (enExample)
SG (1) SG172810A1 (enExample)
UA (1) UA109109C2 (enExample)
WO (1) WO2010083276A1 (enExample)
ZA (1) ZA201105099B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079193A2 (en) * 2009-12-23 2011-06-30 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
DK3158991T3 (da) 2010-01-28 2021-06-14 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
WO2012176214A2 (en) * 2011-06-20 2012-12-27 Hetero Research Foundation Process for bendamustine hydrochloride
ES2943668T3 (es) 2012-03-20 2023-06-15 Eagle Pharmaceuticals Inc Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración
HUE064884T2 (hu) * 2012-03-20 2024-04-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelések
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2014164957A1 (en) * 2013-03-12 2014-10-09 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
WO2014176070A1 (en) 2013-04-26 2014-10-30 Vital Art & Science Incorporated Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159877C (enExample)
DE293808C (enExample)
DE80967C (enExample)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
PT752248E (pt) * 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP3999263B2 (ja) * 1993-10-27 2007-10-31 ファルマシア・アンド・アップジョン・カンパニー 安定化したプロスタグランジンｅ▲１▼
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US20040058956A1 (en) * 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
WO2002048142A1 (en) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
WO2003034944A1 (de) * 2001-10-15 2003-05-01 Hemoteq Gmbh Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
ATE389183T1 (de) 2002-03-22 2008-03-15 Univ Muenchen L Maximilians Zytokapazität-verfahren
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1501566B1 (de) 2002-05-09 2008-08-13 Hemoteq AG Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
TW200427463A (en) * 2003-02-14 2004-12-16 Salmedix Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
EP1648454A1 (en) * 2003-07-25 2006-04-26 Wyeth Cci-779 lyophilized formulations
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN102177140B (zh) * 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure

Also Published As

Publication number Publication date
AU2010204765A1 (en) 2011-07-28
BRPI1004922A2 (pt) 2019-09-24
IL213725A0 (en) 2011-07-31
KR20110110293A (ko) 2011-10-06
EP2387400A1 (en) 2011-11-23
MX2011007557A (es) 2011-08-12
UA109109C2 (uk) 2015-07-27
US20100210701A1 (en) 2010-08-19
WO2010083276A1 (en) 2010-07-22
JP2012515210A (ja) 2012-07-05
ZA201105099B (en) 2012-03-28
SG172810A1 (en) 2011-08-29
CA2749101A1 (en) 2010-07-22
CN102281877A (zh) 2011-12-14
NZ594010A (en) 2013-08-30
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
CN103554030A (zh) 2014-02-05
US8076366B2 (en) 2011-12-13
AU2016204902A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
CN102281877B (zh) 苯达莫司汀的游离碱形式
ES2550003T5 (es) Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
EP3585787A1 (en) Crystalline forms of valbenazine salts
WO2013132511A1 (en) Novel polymorph of lurasidone hydrochloride
Wu et al. New insight into improving the solubility of poorly soluble drugs by preventing the formation of their hydrogen-bonds: A case of dapsone salts with camphorsulfonic and 5-sulfosalicylic acid
EA025561B1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
RS60939B1 (sr) Čvrsti oblici soli nilotiniba
EP3601271B1 (en) Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
US10703750B2 (en) Crystalline valbenazine free base
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
CA2843777C (en) Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
US20200283381A1 (en) Solid state forms of elafibranor
EP2729460B1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor
CA2552663A1 (en) Crystalline forms of rizatriptan benzoate
WO2024023796A1 (en) Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof
CN101115706A (zh) 制备普伐他汀钠的方法
EP3870298A1 (en) New crystalline polymorphs of rigosertib sodium
CN114174295A (zh) 维奈托克的多晶型体和用于制备该多晶型体的方法
HK1192234B (en) Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140723

Termination date: 20170114

CF01 Termination of patent right due to non-payment of annual fee